Asymptomatic screening for SARS CoV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice.

Dig Liver Dis

Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia. Electronic address:

Published: November 2020

Download full-text PDF	Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7450924	PMC
http://dx.doi.org/10.1016/j.dld.2020.08.035	DOI Listing

Publication Analysis

asymptomatic screening

screening sars

sars cov-2

cov-2 prior

prior commencement

commencement biologic

biologic therapies

therapies patients

patients inflammatory

inflammatory bowel

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!